NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that full results from the Phase 2 clinical trial for the assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD) will be presented at the ICNC10 - Nuclear Cardiology and Cardiac CT Conference, being held May 15-18 in Amsterdam. The full Phase 2 data set will be presented in a late-breaking presentation by Jamshid Maddahi, M.D., F.A.C.C., Professor of Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (Cardiology) at the David Geffen School of Medicine at UCLA, and the Lead Principal Investigator of the study.
